Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2.
Aortic stenosis (AS) is the most common valvular heart disease, and it is suspected that atherosclerotic mechanisms are involved in the development of this disorder. Therefore, the retention of lipids within the aortic valve may play a role in the pathobiology of AS. In this study, a gene expression microarray experiment was conducted on human aortic valves with and without AS. The expression levels of transcripts encoding proteoglycans and enzymes involved in lipid retention were compared between the two groups. The microarray results were subsequently replicated in a cohort of 87 AS valves and 36 control valves. In addition, the interaction between proteoglycan and lipid-modifying enzyme was documented in isolated valve interstitial cells (VICs). The microarray results indicated that only biglycan (BGN) and phospholipid transfer protein (PLTP) were overexpressed in the AS valves. These results were then confirmed by quantitative PCR. The immunohistochemical analysis revealed a colocalization of BGN, PLTP, and Toll-like receptor-2 (TLR 2) in AS valves. In vitro, we showed that BGN induces the production of PLTP in VICs via the stimulation of TLR 2. Thus, increased accumulation of BGN in AS valves contributes to the production of PLTP via TLR 2. These results suggest that intricate links between valve matrix proteins, inflammation, and lipid retention are involved in the pathobiology of AS.
Derbali
Habib
H
Laboratoire d'Etudes Moléculaires des Valvulopathies, Groupe de Recherche en Valvulopathies, Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Ste-Foy Québec, Quebec, Canada, G1V-4G5.
Bossé
Yohan
Y
Côté
Nancy
N
Pibarot
Philippe
P
Audet
Audrey
A
Pépin
Andree
A
Arsenault
Benoit
B
Couture
Christian
C
Després
Jean-Pierre
JP
Mathieu
Patrick
P
D001024:Aortic Valve Stenosis / Q000378:metabolism* / Q000473:pathology; D058578:Biglycan; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D020869:Gene Expression Profiling; D006801:Humans; D046228:Microarray Analysis; D049294:Phospholipid Transfer Proteins / Q000235:genetics / Q000378:metabolism*; D011509:Proteoglycans / Q000378:metabolism*; D051195:Toll-Like Receptor 2 / Q000235:genetics / Q000378:metabolism*
C546884:BGN protein, human; D058578:Biglycan; D016326:Extracellular Matrix Proteins; D049294:Phospholipid Transfer Proteins; D011509:Proteoglycans; D051195:Toll-Like Receptor 2
Curr Opin Lipidol. 2004 Oct;15(5):505-14
15361785
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1601-7
12855484
Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):578-86
17170377
Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):462-8
11884291
Atherosclerosis. 2004 Nov;177(1):29-35
15488862
Circulation. 2003 Jul 22;108(3):270-4
12835223
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1213-9
15718493
Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2211-8
15472124
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):187-93
17975118
Arterioscler Thromb Vasc Biol. 1995 May;15(5):551-61
7749869
Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):809-15
12663372
J Lipid Res. 2004 May;45(5):805-11
14993244
Cardiol Rev. 2008 Nov-Dec;16(6):273-9
18923230
Circulation. 2007 Oct 16;116(16):1832-44
17938300
Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):162-8
19023094
Ann Thorac Surg. 2008 Jul;86(1):71-6
18573401
J Lipid Res. 2003 Aug;44(8):1453-61
12730304
J Am Coll Cardiol. 2009 Feb 10;53(6):491-500
19195606
Atherosclerosis. 1992 Apr;93(3):189-99
1590824
N Engl J Med. 2008 Sep 25;359(13):1395-8
18815402
J Clin Invest. 2005 Aug;115(8):2223-33
16025156
Am J Physiol Cell Physiol. 2008 Jan;294(1):C29-35
17942642
J Biol Chem. 2001 Jul 20;276(29):26898-905
11325961
Circulation. 2001 Dec 18;104(25):3103-8
11748108